Thioredoxin Systems AB (TXN Systems): Valuation, Funding & Investors
Thioredoxin Systems AB (TXN Systems) is a pharmaceutical company focused on developing EbsArgent™, a first-in-class bactericidal antibiotic designed to treat urinary tract infections caused by multidrug-resistant bacteria. The company's innovative approach targets a critical need in combating antibiotic resistance, aiming to provide effective solutions for challenging infections.
Leadership & Board
- Current Number of Employees
- 9
- Current LinkedIn Followers
- 304
Latest Estimated Valuation
- Total Amount Raised
- $25M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $25M
- Latest Funding Round
- Series A
Employee Trend
Thioredoxin Systems AB (TXN Systems) had 9 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Thioredoxin Systems AB (TXN Systems) had 304 followers as of October 26, 2026. The number of followers increased by 3 (1.00%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 14, 2025 | Series A | $25.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Mikael Lönn | Series A |
| Jens Mogensen | Series A |
| GU Ventures | Series A |
| Vasa Angels | Series A |
| Annexstruktur | Series A |
| Gobia Enterprises | Series A |
Similar Companies
A snapshot of private companies similar to Thioredoxin Systems AB (TXN Systems), helping you discover and navigate related company profiles.
Related News and Analysis
